For this issue of JMS, we have invited Professor Bruno Domon (Luxembourg Clinical Proteomics, Luxembourg) to contribute a tutorial special feature article on the use of selected ion monitoring (SRM) applied to proteomics. For several decades, SRM has been the reference quantitative technique to analyze small molecules. Targeted SRM allows quantitative analysis and off ers high selectivity, sensitivity and a wide dynamic range. In this article, through examples from his laboratory, Professor Domon is giving an in-depth overview of state of the art SRM technology, describing how it is becoming an emerging tool in proteomics to complement shotgun qualitative studies. The specifi cities and technical aspects of SRM applied to proteomics experiments are addressed. This outstanding article will, I am convinced, become a SRM benchmark for seasoned mass spectrometry users as well as for newcomers to the fi eld.
Sebastien
Gallien has joined the Luxembourg Clinical Proteomics Center as postdoctoral researcher at CRP-SantΓ©, in Luxembourg. He received his M.S. and Ph.D. in Analytical Chemistry at the University of Strasbourg, in the Laboratoire de spectromΓ©trie de masse bio-organique in 2005 and 2009, respectively. His current research is focused on developments of targeted proteomics methodologies. Elodie Duriez has joined the Luxembourg Clinical Proteomics Center as postdoctoral researcher at CRP-SantΓ©, in Luxembourg. She obtained her Ph.D. from Paris VI University (France) in 2009. During the PhD thesis, she worked on the development of analytical methods for protein toxins detection and quantifi cation based on LC-MS in environmental samples and biofl uids in the Drug metabolism research laboratory, at the CEA (Commissariat Γ l'Energie Atomique, Paris). Her current research is focused on clinical proteomics for the evaluation phase of biomarkers.
Dr. Bruno Domon is an expert in biological mass spectrometry and proteomics. He has a Ph.D. from the University of Lausanne, and started his career in mass spectrometry as postdoctoral researcher at the Massachusetts Institute of Technology (MIT). He is presently Director of the Luxembourg Clinical Proteomics Center, CRP-SantΓ©, in Luxembourg. His main focus is the development of novel mass spectrometric based proteomics methodologies, their application to biomarker discovery and evaluation, and to proteomics in general. He was principal investigator at the Institute for Molecular Systems Biology at ETH Zurich, Switzerland (2005-2009), and he led the proteomics program on drug target discovery in oncology at Celera Genomics in Rockville, MD, USA (2001)(2002)(2003)(2004). Prior to that, he was in charge of mass spectrometry facilities at Biogen in Cambridge, MA, USA, and at Ciba-Geigy (now Novartis) in Basel, Switzerland. He is author and co-author of more than 60 publications published in peer-reviewed journals and inventor of several patents or patent applications.